Enfuvirtide (Fuzeon)

Enfuvirtide was the first approved peptide drug that stops HIV by physically blocking viral membrane fusion — a real, historically important 2003 approval backed by two solid randomized trials in patients who had run out of other options. It's also a case study in a drug whose efficacy was never really in question but whose real-world burden — twice-daily subcutaneous injections, and injection-site reactions in the large majority of patients — pushed it to the back of the treatment line as soon as effective oral alternatives existed.

What it is, and its real 2003 approval

Enfuvirtide (T-20) is a synthetic 36-amino-acid peptide that binds HIV-1's gp41 envelope protein, blocking the conformational change the virus needs to fuse with and enter a host CD4 cell — a mechanism entirely distinct from the reverse-transcriptase and protease inhibitors that dominated HIV therapy at the time. FDA approved it as Fuzeon (Trimeris/Roche) on March 13, 2003, for use in combination with other antiretrovirals in patients with evidence of ongoing HIV-1 replication despite existing therapy.

The TORO trials

Approval rested on two 24-week randomized trials in heavily treatment-experienced, multidrug-resistant patients: TORO 1 (Lalezari et al., N Engl J Med 2003;348:2175-2185, PMID 12637625, 501 patients, North/South America) and TORO 2 (Lazzarin et al., N Engl J Med 2003;348:2186-2195, PMID 12773645, Europe/Australia). Both randomized patients to an optimized background antiretroviral regimen with or without enfuvirtide; both found significantly greater viral-load reduction and immunologic improvement with enfuvirtide added.

A real, near-universal tolerability problem

Enfuvirtide requires twice-daily subcutaneous injection, and injection-site reactions (pain, erythema, induration, nodules) occur in the large majority of patients — real, drug-defining side effects, not a minor footnote. This is the central reason enfuvirtide fell out of routine use once effective, better-tolerated oral regimens (particularly integrase inhibitors) became widely available.

Where it sits today

Enfuvirtide remains FDA-approved and is still marketed — it has not been formally discontinued the way this site's exenatide or pramlintide pages describe for those drugs. But it now occupies a narrow, salvage-therapy niche: patients with extensively drug-resistant HIV who have exhausted oral options. It's a useful, real illustration of a drug whose efficacy case was never in doubt, but whose delivery burden alone was enough to make it a last resort rather than a mainstream therapy.